Prof. Eyal Gottlieb is the Director of the Rappaport Institute for Biomedical Research and the Laura and Isaac Perlmutter Chair of Cancer Research, at the Ruth and Bruce Rappaport Faculty of Medicine, Technion – Israel Institute of Technology, Haifa, Israel.
Prof. Gottlieb received his PhD from the Weizmann Institute of Science in 1999. He trained as an EMBO postdoctoral Fellow at the University of Chicago and as a Leukemia and Lymphoma Society Special Fellow at the University of Pennsylvania. He started his independent research in 2003 at the Cancer Research UK, Beatson Institute in Glasgow where he eventually founded and was the first Director of the Cancer Metabolism Research Department and a Professor of Molecular Cell Biology at the University of Glasgow. In 2016, Prof. Gottlieb was appointed as a Professor at the Technion where he continues to study metabolism in health and disease. Specifically, Prof. Gottlieb explores metabolic vulnerabilities of cancer cells induced by genetic or environmental changes. Many of his discoveries are clinically relevant and were translated to several drug discovery programs in academia and industry.
Among Prof. Gottlieb’s key accomplishments is the identification of onco-metabolic signaling, the elucidation of adaptations to the genetic loss of the metabolic tumor suppressors fumarate hydratase and succinate dehydrogenase, and to metabolic stressful environments.
Beyond his academic research activities, Prof. Gottlieb is a Senior Editor at Cancer Research and a member of several Editorial Boards. He is a co-Founder and Executive Board member of two Biotech companies, MetaboMed and Pangea Therapeutics.
